97,861 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Bought by M&G Plc

M&G Plc purchased a new stake in Blueprint Medicines Co. (NASDAQ:BPMC) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 97,861 shares of the biotechnology company’s stock, valued at approximately $9,101,000. M&G Plc owned approximately 0.16% of Blueprint Medicines at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of BPMC. Allspring Global Investments Holdings LLC purchased a new stake in Blueprint Medicines during the first quarter worth approximately $218,000. SG Americas Securities LLC raised its stake in Blueprint Medicines by 117.6% during the 1st quarter. SG Americas Securities LLC now owns 11,865 shares of the biotechnology company’s stock worth $1,126,000 after acquiring an additional 6,412 shares in the last quarter. Swiss National Bank lifted its position in Blueprint Medicines by 0.4% in the first quarter. Swiss National Bank now owns 114,000 shares of the biotechnology company’s stock valued at $10,814,000 after acquiring an additional 500 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Blueprint Medicines in the first quarter valued at $474,000. Finally, Sei Investments Co. increased its position in shares of Blueprint Medicines by 36.6% during the first quarter. Sei Investments Co. now owns 45,913 shares of the biotechnology company’s stock worth $4,355,000 after purchasing an additional 12,311 shares in the last quarter.

Blueprint Medicines Stock Up 1.8 %

Shares of NASDAQ BPMC opened at $101.39 on Friday. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The firm has a 50-day moving average price of $89.10 and a 200 day moving average price of $98.67. Blueprint Medicines Co. has a 52 week low of $56.74 and a 52 week high of $121.90. The stock has a market capitalization of $6.44 billion, a price-to-earnings ratio of -48.05 and a beta of 0.59.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same quarter in the previous year, the company earned ($2.20) EPS. The company’s quarterly revenue was up 126.5% on a year-over-year basis. Equities research analysts anticipate that Blueprint Medicines Co. will post -3.61 EPS for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the transaction, the insider now owns 69,070 shares of the company’s stock, valued at $6,169,332.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.21% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Wednesday, October 30th. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday. Barclays lifted their price objective on shares of Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, July 29th. Morgan Stanley increased their target price on shares of Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. Finally, UBS Group started coverage on Blueprint Medicines in a research report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $120.39.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.